Qiagen had its Relative Strength (RS) Rating upgraded from 77 to 81 Wednesday.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains typically have an 80 or better RS Rating as they launch their biggest price moves.
Qiagen is not currently showing a potential entry point. See if the stock goes on to build a sound pattern that could launch a new move.
Earnings growth decreased in the most recent quarter from 17% to 9%. But revenue gains moved higher, from 5% to 7%.
Qiagen earns the No. 18 rank among its peers in the Medical-Products industry group. Insulet, TransMedics Group and ResMed are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
